Abbott announced today that it has updated NeuroSphere, its app-driven neuromodulation therapy platform, with remote programming capabilities that will allow patients to speak with and receive ...
Abbott has received FDA approval for a neuromodulation system-controller app that runs on iOS devices, the company announced Thursday. Compatible with Abbott's broader NeuroSphere Digital Care ...
ABBOTT PARK, Ill., June. 22, 2016 — Abbott announced today positive results from three clinical studies investigating the benefits associated with focal impulse rotor modulation (FIRM)-guided rotor ...
Abbott Laboratories ABT has been delivering consistent organic growth in the Established Pharmaceuticals Division (EPD) and Diabetes segments. However, the soft neuromodulation business is a challenge ...
Abbott Laboratories (NYSE:ABT) announced Thursday that the FDA approved expanded MRI labeling for its pain relief device Eterna spinal cord stimulation (SCS) system, allowing its use in patients who ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback